Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Desvigne

Plastic and Reconstructive Surgery Glendale, AZ Medical Doctor

NPI 1356336317 CMS profile 287796

6320 W. Union Hills Dr, Bldg A, Ste 140, Glendale, AZ 85308

Open in the dashboard

General payments

$2,201,075

1,401 records reported · program years 2019–2025

Research payments

$35,120

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$16,328 paid to institutions, not to them · program years 2022–2024

Through program year 2025, Michael Desvigne of Glendale, AZ is reported in the CMS Open Payments database as having received $2,201,075 across 1,401 general payments and $35,120 in research payments paid to them. Separately, studies naming them as principal investigator received $16,328 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $273,962 183
2024 General $305,891 187
2023 General $365,484 259
2022 General $285,300 168
2021 General $245,219 149
2020 General $217,915 113
2019 General $507,305 342
2019 Research $35,120 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Desvigne
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Michael Desvigne were reported at $273,962. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Michael Desvigne Plastic and Reconstructive Surgery median Middle half National median
2019 $507,305 $335 $121–$1,264 $163
2020 $217,915 $162 $57–$417 $114
2021 $245,219 $245 $89–$735 $132
2022 $285,300 $325 $120–$932 $149
2023 $365,484 $343 $129–$999 $160
2024 $305,891 $390 $141–$1,085 $164
2025 $273,962 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Musculoskeletal Transplant Foundation Inc. $1,106,205 451 payments
  2. KCI USA, Inc $577,630 433 payments
  3. Solventum Corporation $244,552 144 payments
  4. Smith+Nephew, Inc. $176,062 239 payments
  5. Urgo Medical North America, LLC $54,517 31 payments
  6. Aroa Biosurgery Incorporated $22,613 29 payments
  7. Integra LifeSciences Corporation $8,830 5 payments
  8. Wound Management Technologies, Inc $6,184 4 payments
  9. Kerecis Limited $1,238 9 payments
  10. Medline Industries, Inc. $655 6 payments
  11. Other $2,590 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,247,419 251 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $626,059 146 payments
  3. Travel and Lodging $260,022 594 payments
  4. Food and Beverage $52,459 406 payments
  5. Education $15,073 3 payments
  6. Entertainment $43 1 payment
Products named General payments · program years 2019–2025
  1. V.A.C. VERAFLO $283,304 140 payments
  2. PROMOGRAN PRISMA $180,824 85 payments
  3. PREVENA Negative Pressure Systems & Dressings $178,646 111 payments
  4. ACTIV.A.C. $165,375 107 payments
  5. V.A.C. VERAFLO CLEANSE CHOICE $161,969 56 payments
  6. V.A.C. DERMATAC $154,490 84 payments
  7. VAC VERAFLO $103,844 71 payments
  8. 3M Cavilon $99,652 38 payments
  9. COLLAGENASE SANTYL $84,062 98 payments
  10. PREVENA Non-Covered $67,654 65 payments
  11. Other $780,034 682 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Musculoskeletal Transplant Foundation Inc. $35,120 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

70

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$18,674

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

17.1%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 12 $18,333
Cephalexin Generic 15 $179
Ciprofloxacin Hcl Generic 30 $125
Tramadol Hcl Generic 13 $37

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$18,115

Medicare's payments for the services billed

Medicare patients

31

Average age 71

Services billed

171

20 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 71%
Chronic kidney disease 45%
Depression 45%
Diabetes 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1,402 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record